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Readers’ Comments 2169recent study, Wang et al8 reported
that connective tissue growth factor
expression was significantly associ-
ated with atrial fibrosis and higher in
EAT of patients with AF which
presents another evidence for the
relation between EAT and AF. Thus,
Maeda et al1 may comment on the
possible impact of metabolic
derangements when combined as
metabolic syndrome on outcome of
catheter ablation and also adjust their
EATV values with BMI. The study
also lacks any proinflammatory or
profibrotic biomarker correlating
such mechanisms with EATV.
Besides all those metabolic factors,
the study may also provide the
details of ablation procedure as pul-
monary vein isolation (PVI) only
versus PVI+ additional ablation line
groups to delineate the impact of
them on ablation outcome. Thus,
EAT becomes a pathologic endocrine
organ in presence of several meta-
bolic derangements in subjects and
may predict the occurrence of more
severe left atrial remodeling and AF
recurrence after catheter ablation.Conflict of interest
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MendelianRandomization in CaseOnly Studies:
A Promising Approach
to be Applied With
CautionIn response to a recent study by
Zafrir et al1 reporting an inverse asso-
ciation between excess adiposity and
mortality rate in patients that under-
went cardiac catherization, Trischitta
and Di Paolo2 provide an insightful
comment on the importance of
addressing the “obesity paradox.”
This study1 as well as others3,4 show
that increased adiposity appears seem-
ingly protective against all-cause mor-
tality4 as well as in patients with high-
risk conditions including coronary
artery disease,1,5 type-II diabetes6 and
end-stage renal disease.7 Trischitta
and Di Paolo suggest that this para-
doxical effect in frail and high-risk
patients could be due to adipocytokine
profile improving drugs or the pres-
ence of a preexisting disease that
causes weight loss, and therefore the
result of survival bias. Other factors
may also results in bias such as con-
founding by age, ill-health and life-
style factors as well as selection bias.8
−10
To overcome these limitations, Tri-
schitta and Di Paolo emphasize the
need to investigate the causal relationof adiposity and/or body mass index
(BMI) on mortality rate in high-risk
patients directly through randomized
controlled trials or using genetic var-
iants in an instrumental variable
approach through Mendelian randomi-
zation (MR).2 MR is a useful approach
in investigating causal relations in the
absences of confounding and reverse
causality11 and as they point out, recent
MR studies have supported the causal
role of higher BMI on higher risk of
coronary heart disease using publicly
available GWAS data12 and (more
recently) on increasing the risk of all-
cause mortality and specifically cardio-
vascular disease in UK Biobank.13
We agree with Trischetta and Di
Paolo, that epidemiological studies
within selected groups of individuals
(e.g., cases of a particular disease, or
individuals at known increased risk) is
a promising approach to identify causal
relations. However, it must also be
taken into account that proposing to
apply epidemiological methodologies
(including MR) in “well-powered sam-
ples of frail patients”2 will also be sub-
ject to potential collider bias by design,
due to studying a selected group of
individuals, as we have recently
described.14 Indeed, disease incidence
becomes a collider variable due to its
association with other independent risk
factors for being a case of that disease
(genetic and nongenetic), resulting in
those risk factors becoming spuriously
associated in the cases. When the risk
factors are also associated with the out-
come, conditioning on this collider (i.
e., selecting case only individuals)
opens up a noncausal path (Figure 1).14
In the case of a genetic study within
cases, this will result in spurious associ-
ations between genetic variants and the
outcome.15 Therefore, increased care
needs to be taken to address potential
confounding in studies of nonrandom
group of individuals.
Specifically, in the context of MR
studies, the assumption that the genetic
instrument is independent of factors
that confound the associations of the
exposure and the outcome may be vio-
lated.14 If the exposure causes the onset
of disease, then the genetic instruments
for the exposure may become associ-
ated with other independent risk factors
for onset in a group of cases.14 In other
words, a spurious association is induced
between the gene and confounders of
Figure 1. DAG demonstrating the introduction of collider bias in case-only studies. (A) Risk factors, both genetic and nongenetic, become spuriously associ-
ated due to risk factors being independently associated with disease incidence (dashed line). This opens up a noncausal pathway from exposure to outcome
when a risk factor is also associated with the outcome. (B) In MR analysis, the genetic instruments cause the disease and therefore they become spuriously
associated with independent risk factors which are confounders of the exposure-outcome. Conditioning on incidence opens noncausal pathways between all
variables that cause incidence. DAG = direct acyclic graph; MR = Mendelian randomization.
2170 The American Journal of Cardiology (www.ajconline.org)the exposure-outcome association lead-
ing to a noncausal association between
the gene and the outcome (Figure 1).16
When investigating obesity as the expo-
sure and mortality rate as the outcome
in high-risk patients, selecting individu-
als based on having coronary heart dis-
ease for example, may induce spurious
associations between BMI (and there-
fore, genetic variants related to BMI)
and confounders such as age, educa-
tional attainment, smoking, and alcohol
intake.
This collider bias can lead to biased
and misleading estimates of causal
associations17 and to an over- or under-
identification of risk factors for the out-
come of interest in a nonrandom sam-
ple.14 Therefore, it is important to
assess the presence, magnitude, and
direction of the bias, which will depend
on the exact nature of the combined
effects of variables on disease status
and the relation between variables.14
We suggest a number of ways to detect
and correct for this bias, including
inverse probability weighting when the
effects of confounders on disease onset
are known.14 This is an area of currentongoing methodological research and
should be taken into consideration not
just in MR studies but in any studies of
case only samples.
Trischitta and Di Paolo finish by
highlighting that results from MR stud-
ies can inform the selection of targets
for randomized controlled trials.2 This
is a very promising approach18 and as
pointed out “MR studies conducted in
well-powered samples of frail patients
are timely needed.”2 These types of
studies offer considerable opportunity
to identify treatment targets and
inform therapeutics. Therefore, large-
scale sources of data with measures of
progression along with genetic data
need to be sought out and studies
designed to appropriately address col-
lider bias.
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